Type 2 diabetes (T2D) is characterized by reductions in β-cell function and insulin secretion on the 25 background of elevated insulin resistance. Aerobic exercise has been shown to improve β-cell function, 26
INTRODUCTION 43
Insulin is an essential glucoregulatory hormone. In the presence of insulin resistance, this pancreatic β-44 cell secreted hormone has a diminished ability to drive plasma glucose into peripheral tissues. The 45 subsequent glycemic dysregulation is overcome by β-cell compensation via insulin hyper-secretion. In a 46 subset of individuals, however, the β-cell is unable to sustain this compensatory state and eventually 47 undergoes failure. This progression underlies the pathogenesis of type 2 diabetes (T2D) and is the topic 48 of several in-depth reviews (8, 12, 15) . Investigating therapies that target recovery of β-cell function in 49 the T2D patient population is of paramount clinical importance, as 21 million American adults have 50 already been diagnosed with the disease (7). 51 52 Several groups have demonstrated that exercise has a profound effect on insulin secretion and β-cell 53 function (16, 29) , in addition to its already established influence on insulin sensitivity (17, 28) . The 54 specific effects of exercise on β-cell function appear to be dependent on metabolic status and the mode 55 of exercise implemented. We have shown that a twelve-week aerobic exercise intervention improved β-56 cell function in adults with T2D (31). The same intervention also suppressed insulin hyper-secretion in 57 healthy overweight adults. We further demonstrated that exercise-driven improvements in glycemic 58 control were better predicted by insulin secretion rather than sensitivity (32). Specifically, participants 59 with greater pre-intervention pancreatic secretory function also had the greatest improvements in 60 glycemic control. When comparing responses to physical training in T2D patients with moderate versus 61 low secretory capacity, Dela et al. reached a similar conclusion, showing that only the moderate 62 secretors responded favorably to exercise training (9). From these findings there appears to be a 63 response dichotomy to exercise in the T2D population, specifically dependent on residual β-cell 64 secretory capacity. 65
66
The aforementioned studies employed only aerobic exercise training. A recently published study of 8-67 weeks of High Intensity Interval Training (HIIT), which has risen in popularity in both the exercise science 68 field and society at large, in adults with T2D showed improvements in β-cell function, despite no 69 changes in insulin secretion or sensitivity (21). The combination of aerobic and resistance training in the 70 STRRIDE-AT/RT randomized trial resulted in increased β-cell function to a greater extent than either 71 training mode alone, in sedentary, obese, non-diabetic adults (1). Combination training or high intensity 72 training may be able to overcome the apparent resistance to exercise seen in some individuals in 73 aerobic training only studies, but this has yet to be investigated. 74
75
The exercise approach that was developed by CrossFit, Inc.™, differs significantly from the exercise 76 protocols used in studies to date, and may be described as a Functional High Intensity Training (F-HIT) 77
protocol. This type of supervised training is defined by constantly varied, functional movements 78 performed at a high intensity, and combines resistance training, gymnastics (body weight), and aerobic 79 exercise. Importantly, workouts only require 10 to 20 minutes per session and are only performed 3 80 times per week (30). To date, there are no published studies that have assessed β-cell function in F-HIT 81 or resistance training within the T2D patient population. We hypothesized that this novel F-HIT 82 intervention program would increase β-cell function in adults with T2D. 83 84
METHODS 85
Subjects. This pilot, proof-of-principle study, involved twelve adults with clinically diagnosed T2D (8 86 women, 4 men, HbA 1c 8.6±0.7%, 53 ± 2 years), recruited from the Cleveland Metropolitan Area. All 87 participants were receiving standard of care treatment including metformin and diet/exercise 88 education, but none were taking insulin to control their diabetes. Exclusion criteria included heart, 89 kidney, liver, thyroid, intestinal, and pulmonary diseases or medications known to affect the outcome 90 variables of the study. All participants underwent medical history, physical exam, and clinical blood-work 91 prior to entering the study. Participants were sedentary (less than 1 hour of exercise a week) and weight 92 hours prior to testing, and the participants also refrained from structured exercise during that time. exercise stress test (SensorMedics, CareFusion, San Diego, CA) to assess healthy heart function and 145 safety to exercise. The test was performed on a treadmill at constant speed while the grade was 146 increased in two minute stages until the individual reached 80-85% of their age-predicted heart rate 147 max. Blood pressure was also recorded during every 2-minute stage of the test. A second incremental 148 graded treadmill exercise test was administered on a separate day and was performed before and after 149 the exercise intervention to measure maximal oxygen consumption (VO 2max ; Jaeger Oxycon Pro, Viasys, 150
Yorba Linda, CA) (17). The test was deemed maximal if there is a plateau of VO 2 despite increased work 151 load and at least two of the following additional criteria were satisfied: volitional fatigue, heart-rate 152 greater than age-predicted maximum, and RER of ≥1.10. Blood pressure and heart rate were also 153 monitored during the test. Performance during each exercise training session was recorded by the 154 CrossFit™ trainer. Days 2 and 18 (final session) consisted of the same sets of exercises with total 155 repetitions recorded: 5 sets of 1 minute of rowing, 1 minute of sit-ups, 1 minute of squats (no weight), 156 and 1 minute of rest. One subject did not complete a post-intervention VO 2max test due to equipment 157 failure, and another subject did not have the number of repetitions recorded for their final exercise 158 training session. 159 160 Statistics. Data are presented as means ± standard error of the mean. Statistical analyses were 161 performed using GraphPad Prism 5. Data sets were tested for normality using the Shapiro-Wilk test. 162
Non-normal data were natural log transformed to approach normality, which was subsequently 163 confirmed using the Shapiro-Wilk test. PRE-to POST-intervention statistical comparisons were analyzed 164 with a paired two-tailed Student's t-test. Linear regression analyses between study variables (Δ vs. Δ) 165
were also performed in GraphPad Prism 5, using the Pearson test for correlations. Non-normally 166 distribute Δ data sets were also natural log transformed to approach normality. The accepted P value for 167 significance for each two-tailed test and Pearson correlation was set a priori at less than 0.05. 168
169

RESULTS
170
Physiological and Metabolic Adaptations. F-HIT intervention effects on subject anthropometrics and 171 fasting plasma measures are listed in Table 1 . Body composition changed significantly, with a mean 172 reduction in total body fat percentage (Δ: -1.1 ± 0.3 %, P = 0.002) along with trending total body weight 173 loss (Δ: -1.8 ± 1.0 kg, P = 0.09). Exercise capacity was significantly greater after training, with increases in 174 both VO 2max (Δ: 0.38 ± 0.08 L/min, P = 0.001) and total repetitions completed for standardized training 175 sessions (Δ: 59 ± 8, P < 0.001). Mean fasting plasma measures of glucose, insulin, C-peptide, proinsulin, 176 and free fatty acids, which are of general clinical importance to patients with T2D, did not change 177 significantly. Measures of liver enzyme levels in the plasma (ALP, AST, ALT) were significantly, or tended, 178 to be reduced. First-phase (0-30min) and late-phase (30-180min) plasma glucose, insulin, C-peptide, and 179 proinsulin remained unchanged as well (Table 1) . 180
181
Insulin Secretion. The early-phase DI was significantly improved following the intervention (PRE: 8.4 ± 182 3.1, POST: 11.5 ± 3.5, P = 0.02; Fig. 1A ). Late-phase DI was not increased (PRE: 15.6 ± 3.1, POST: 16.4 ± 183 2.5, P = 0.65). There was, however, variability in individual responses to the intervention with regard to 184 DI (Fig. 1C) . Individuals with ΔDI above the mean are indicated as filled circles, with those below the 185 mean with little to no change in DI indicated as crossed circles. Since DI is the product of early-phase 186 secretion and insulin sensitivity, the individual Δ's for these measures are presented in Figure 1D and 1E. 187
The individual demarcations from Figure 1C Figure 2C shows the spread of individual responses to the F-HIT intervention based 209 on the DI derived β-cell function index. Sub-group analyses were performed to compare the individuals 210 demarcated in Figure 1 as filled circles ("responders", n=5) versus crossed circles ("non-responders", 211 n=7). Participants in the "responder" sub-group were all female, with no significant differences from the 212 "non-responders" in terms of age or body composition. This "responder" sub-group had higher PRE-213 intervention fasting plasma ALP levels (92 ± 5 vs. 64 ± 7 U/L, P = 0.008), as well as higher fasting C-214 peptide levels (4.0 ± 0.3 vs. 2.7 ± 0.5 ng/dL, P = 0.05). This sub-group also had better overall glucose 215 tolerance, as tAUC (0-180 min) glucose was lower for this sub-group PRE-(33603 ± 2228 vs. 44157 ± 216 4060 mg/dL*min, P=0.05) and POST-intervention (32242 ± 2051 vs. 43290 ± 3502 mg/dL*min, P=0.02). 217
Secretory capacity, expressed as C-peptide tAUC (0-180 min), was also greater in the "responder" sub-218 group PRE-(792.4 ± 54.0 vs. 550.8 ± 73.9 ng/mL*min, P=0.03) and POST-intervention (787.0 ± 44.5 vs 219 569.0 ± 75.0 ng/mL*min, P=0.03). Early-phase secretion changes were significantly greater in the 220 "responder" sub-group (0.20 ± 0.06 vs. -0.02 ± 0.01 ng/mL/mM, P = 0.02), which is apparent from the 221 distribution of individual changes in secretion presented in Figure 1D . Congruent with the correlations 222 shown in Figure 2 , fasting plasma ALP levels (-18.4 ± 3.3 vs. 0.9 ± 2.6 U/L, P = 0.002) and abdominal fat (-223 2.6 ± 0.85 vs. 0.40 ± 0.65 %, P = 0.02) were significantly reduced in the "responder" sub-group. Following 224 the intervention, the "responder" sub-group also had lower fasting plasma glucose (126 ± 11 vs. 187 ± 225 22 mg/dL, P=0.04). 226
227
DISCUSSION 228
Determining β-cell function in humans poses specific challenges, as only indirect plasma metabolite 229 measures are generally possible. The OGTT has emerged as an efficient and effective method for 230 assessing pancreatic insulin secretion (36). However, insulin secretion is tied directly to insulin 231 sensitivity, in a classic hyperbolic relationship (4). The Disposition Index or DI, which is the mathematical 232 product of secretion and sensitivity, has thus been clinically accepted and validated as a measure of β-233 cell function in humans (33). Here we show that exercise at high intensity for as little as 10-20 mins/day, 234 3 days/wk for 6-weeks improves β-cell function in adults with T2D (Fig. 1A) . The fasting 235 proinsulin/insulin ratio, representing the processing inefficiency of insulin within the β-cell, was also 236 significantly reduced following the intervention (Fig. 1B) , providing further evidence for improved β-cell 237 function. 238 239 Despite achieving mean improvements in β-cell function, overall glucose tolerance was not significantly 240 changed. Following a more traditional 3-month aerobic exercise intervention in T2D patients, Dela et al. 241 used a sub-group analysis to show that only participants with residual β-cell secretory capacity (defined 242 as "moderate secretors") had significantly improved β-cell function, despite no changes in glucose 243 tolerance (9). We also found variability in individual changes in DI, where some participants had limited 244 changes and even reductions in DI in response to the intervention. Therefore, we used a similar sub-245 group analysis approach to delineate possible factors that might contribute to these differences. This 246 analysis revealed that the "responder" sub-group did indeed show improved glucose tolerance, lower 247 glucose tAUC and fasting glucose POST-intervention, following the intervention in contrast to the "non-248 responder" sub-group. These data highlight that participants who did not appreciably improve their β-249 cell function also do not experience improvements in glucose tolerance. 250
251
Resistance to the beneficial effects of exercise could be due to under-performance or compensatory 252 lifestyle changes, as some research groups have suggested (20, 24, 35) . This variability in response to 253 lifestyle intervention has been noted before (5). In this study two measures of physical performance 254 improved very significantly in response to the intervention (Table 1) , but neither β-cell function nor 255 secretion significantly correlated with either of these measures. Within the sub-group analysis, there 256 were also no differences between "training volume", or the total number of repetitions in comparative 257 sessions, between either of the two sub-groups. As a result we cannot attribute response variability 258 specifically to differences in training effort. Instead, as our previously published (32) and currently 259 presented data suggest, residual β-cell secretory capacity is required for exercise (independent of mode) 260 to effectively improve β-cell function and glycemic control. Longer exercise interventions, combined 261 with strict dietary guidelines, may be able to drive improvements in β-cell function in patients with more 262 severe T2D who display resistance to the exercise modes studied to date (25). However, if non-response 263 is driven by genetic factors, as Stephens et al. (34) and Lessard et al. (20) suggest, modifying lifestyle 264 only, may not be a sufficient therapeutic approach. 265
266
The intervention was quite effective at reducing total body fat, with trending reductions in body weight. 267
Notably, lean mass was preserved (Δ: 0.05 ± 0.68 kg, P = 0.94) indicating that any changes in body 268 weight were due to reductions in fat mass. We also found that reductions in abdominal fat correlated 269 significantly with changes in both β-cell function (R 2 = 0.56, P = 0.005) and secretion (R 2 = 0.41, P = 0.02) 270 (Fig. 2) . Accumulation of adipose tissue in the abdominal region has been linked to increased insulin 271 resistance (18), and correlates closely with increased β-cell dysfunction (40), highlighting the negative 272 role of fat in this region on metabolic function. Potential mechanisms include increased plasma FFAs 273 driving lipotoxicitiy of the β-cell (3). However, we did not see any significant statistical association 274 between change in FFAs and β-cell function. We recognize that fasting levels of FFAs do not adequately 275 represent the dynamic regulation of lipolysis (38). However, the percent suppression of plasma FFAs 276 from minute 0 to minute 120 of the OGTT also remained unchanged after the intervention. We have 277 previously reported that exercise and diet intervention-induced improvements in β-cell function among 278 adults with T2D were significantly correlated with changes in GIP (31). However, the incretin hormone 279 levels of GLP-1 and GIP remained unchanged in this study, suggesting that some other mechanism is 280 driving improved β-cell function after this type of intervention. 281
282
Many patients with T2D also have accompanying non-alcoholic fatty liver disease (NAFLD) and 283 hepatocyte apoptosis, which we (10) and others (27) have shown can be reduced by exercise (aerobic 284 and resistance training). Mean plasma AST and ALT levels, which are clinical measures of liver 285 hepatocyte apoptosis, were significantly reduced following the intervention (Table 1) , suggesting overall 286 improvements in liver function (11). Fasting ALP also tended to decrease. The correlations in Figure 2  287 and our sub-group analyses reveal that in the "responder" sub-group, ALP levels were significantly 288 elevated PRE-intervention, but markedly reduced POST-intervention. Cross-sectional analysis of plasma 289 ALP levels show that there appears to be no link to sex (41), despite the sex differences between the 290 two sub-groups. The source of circulating ALP, which may be of liver, bone, or intestinal origin, was not 291 specifically identified in the clinical assay performed. As a result, we are unable to conclude whether ALP 292 levels were indicative of changes in liver, gut, or bone function. The limited available literature on the 293 topic of ALP in T2D is conflicting. One study determined that bone is the predominant source of 294 elevated ALP in T2D (23), although this is not a consistent observation (39). In a mouse model, a high fat 295 diet increases serum ALP levels, but ALP was unaffected by exercise training despite protecting the mice 296 from liver steatosis and loss of β-cell function (22). Our data are contrary to these animal model findings, 297 highlighting the need to further investigate the role of this enzyme in diabetes and exercise, especially 298 as it relates to β-cell function. 299 300 This was a pilot proof-of-principle study investigating the efficacy of a 6-week F-HIT lifestyle intervention 301 in adults with T2D, and hence limitations of this study include the relatively small sample size and lack of 302 comparative groups, in the form of a control group or groups participating in alternative forms of 303 exercise. Instead, we designed the study using an internal validity paradigm, where each participant's 304 PRE-intervention served as the control for the POST-intervention testing results. Second, we note that 305 from a technical perspective, the use of the hyperglycemic clamp technique would have provided a 306 more in-depth determination of pancreatic function. 307
308
There is little scientific doubt that exercise is beneficial, yet adults with T2D may find it difficult to 309 adhere to a strict exercise regimen, citing "lack of time" as one of their primary barriers (19). F-HIT 310 programs like CrossFit™ may address this barrier by providing structure, supervision, and accountability, 311 with a minimal time commitment (10-20 min/session 3 times per week). Additionally, no adverse events 312 or injuries were reported by participants throughout the course of the study. Therefore, we conclude 313 that F-HIT is a safe and effective exercise approach by which adults with T2D may improve their β-cell 314 secretory function, given that residual β-cell secretory capacity is preserved. Here we have identified 315 that changes in plasma ALP levels and abdominal adiposity appear to be additional delineating factors in 316 determining the efficacy of exercise mediated improvements in β-cell function. Larger training studies 317 may shed important insight into the variability in responses to exercise observed in the T2D patient 318 population and to subsequently develop the most effective exercise treatment options for these 319 patients. 320 with Pearson correlation coefficient of determination (R 2 ) and significant P value. N=12.
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